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In vitro and in vivo Evaluation 
of Synergism between Anti-
Tubercular Spectinamides and 
Non-Classical Tuberculosis 
Antibiotics
David F. Bruhn1, Michael S. Scherman2, Jiuyu Liu1, Dimitri Scherbakov3, Bernd Meibohm4, 
Erik C. Böttger3, Anne J. Lenaerts2 & Richard E. Lee1
Spectinamides are new semi-synthetic spectinomycin derivatives with potent anti-tubercular activity. 
The reported synergism of the precursor spectinomycin with other antibiotics prompted us to 
examine whether spectinamides sensitize M. tuberculosis to other antibiotics not traditionally used in 
the treatment of tuberculosis to potentially expand therapeutic options for MDR/XDR Tuberculosis. 
Whole cell synergy checkerboard screens were performed using the laboratory strain M. tuberculosis 
H37Rv, lead spectinamide 1599, and a broad panel of 27 antibiotics. In vitro, 1599 synergized 
with 11 drugs from 6 antibiotic classes. The observed synergy was tested against clinical isolates 
confirming synergy with Clarithromycin, Doxycycline and Clindamycin, combinations of which were 
taken forward for in vivo efficacy determination. Co-administration of 1599 and clarithromycin 
provided additional bacterial killing in a mouse model of acute tuberculosis infection, but not in a 
chronic infection model. Further studies indicated that mismatched drug exposure profiles likely 
permitted induction of phenotypic clarithromycin resistance and subsequent loss of synergism. These 
studies highlight the importance of validating in vitro synergism and the challenge of matching 
drug exposures to obtain a synergistic outcome in vivo. Results from this study indicate that a 1599 
clarithromycin combination is potentially viable, providing the drug exposures can be carefully 
monitored.
More than 130 years since after its identification as the causative agent of tuberculosis in 1882, 
Mycobacterium tuberculosis remains a severe global health threat, has infected more than one third of 
the world’s population, and is responsible for almost 2 million deaths annually1. Although most common 
in the developing world, more than 10,000 cases of tuberculosis and > 500 associated deaths occur in 
the United States annually2. Adept at evasion of the human host’s immune system, M. tuberculosis estab-
lishes persistent infections and forms granulomas in the lung3. There the bacteria can remain in a latent 
state for decades before reactivating and disseminating to cause an active disease state4. The complexity 
and challenge of killing granuloma-resident bacilli is increasingly recognized as the result of multiple 
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subpopulations, even within a single granuloma, each with distinct drug-susceptibility and resistance 
profiles5,6.
Treatment of Mycobacterium tuberculosis infections is lengthy and hindered by the emergence of 
drug resistance7. Standard treatment of drug-susceptible infections requires a 2 month initial phase with 
daily administration of frontline drugs rifampin, isoniazid, pyrazinamide, and ethambutol followed by 
a 4 month continuation phase composed of isoniazid and rifampin. Patient adherence to this lengthy 
regime is challenged by antibiotic-associated toxicity and inadequate access to individual regime com-
ponents, particularly isoniazid for which supply shortages are not uncommon8. Underexposure of drug 
is proposed to permit selection of genetic mutants resistant to frontline drugs and further exacerbates 
the clinical challenge of managing tuberculosis by fueling the development of acquired drug resistance9. 
Drug resistant tuberculosis isolates can be spread from person to person, often with low fitness cost for 
the bacteria, and radically increases the length and cost of treatment for the disease10,11.
In response to the increasing prevalence of multidrug-resistant (MDR) and extensively drug-resistant 
(XDR) tuberculosis infections, numerous efforts are being undertaken to thwart the spread of this 
global killer. Several novel scaffolds with unique mechanisms of action (and thus potential to inhibit 
drug-resistant infections) are in various stages of pre-clinical and clinical development. This includes 
nitroaromatic prodrugs (PA-824, TBA-354, and delamanid), cell wall active compounds such as SQ109, 
the structurally unique aminoglycoside apramycin, and the recently approved bedaquiline (TMC207)12–18. 
Efforts to re-sensitize drug-resistant infections to frontline drugs by adjuvant therapy with non-tubercular 
agents including efflux inhibitors verapamil and thioridazine have also shown promise and are being pur-
sued19,20. Synthetic modification of natural products has led to the successful development of treatments 
for Gram-positive bacterial infections and we have recently applied this approach in the discovery and 
preclinical development of anti-tuberculars known as spectinamides21.
Spectinamides are semi-synthetic derivatives of spectinomycin, an aminocyclitol that binds to a site 
within the bacterial 30S ribosome (helix 34 of 16S rRNA) distinct from that of other protein synthesis 
inhibitors, including aminoglycosides and macrolides22. Unlike aminoglycosides, spectinomycin does not 
inhibit human mitochondrial translation, a side effect of aminoglycosides that leads to ototoxicity23–25. 
Despite its potent activity against bacterial ribosomes, spectinomycin is only weakly antibacterial owing 
to limited intracellular accumulation and resultant access to the ribosomal target. Efflux pump Rv1258c 
is upregulated in MDR/XDR isolates in vitro, implicated in drug tolerance, upregulated in human sputum 
samples during the course of tuberculosis treatment, and provides M. tuberculosis with intrinsic resist-
ance to spectinomycin5,19,21,26,27. Semi-synthetic spectinamide analogs avoid efflux by Rv1258c, thereby 
gaining potency against M. tuberculosis both in vitro and in in vivo models of tuberculosis infection21.
Spectinomycin was previously shown to synergize with several classes of drugs in vitro28. While the 
poor anti-tuberculosis activity of spectinomycin may restrict this synergism in vivo, spectinamides are 
efficacious in vivo and, so, afford the opportunity to further investigate the prospects for sensitization and 
synergism between spectinomycins and antibiotics lacking intrinsic anti-tuberculosis activity. Therefore, 
we investigated the interaction of spectinamides with a library of antibiotics not currently used in stand-
ard TB therapy.
Hits were confirmed in clinical isolates and mechanisms underlying synergy were explored using both 
genetic and biochemical approaches. These studies indicated that lead spectinamides display favorable 
interactions with some FDA approved antibiotics including macrolides in vitro. Combination treatment 
with 1599 and clarithromycin provided additive reduction in bacterial loads in an acute model of tuber-
culosis infection but this interaction was not seen in a lengthier model of chronic tuberculosis infection, 
apparently likely due to mismatched exposure profiles as we show here. These studies highlight the 
challenges of matching in vitro synergism in vivo due to the impact of differing pharmacokinetic profiles 
and dosing schedules on in vivo success of drug combinations identified in vitro.
Results
Chemically diverse antibiotics synergize with anti-tuberculosis spectinamide 1599 in 
vitro. The interaction of lead spectinamide 1599 with a library of 27 antibiotics not normally used to 
treat tuberculosis was examined in vitro using checkerboard synergy assays (Table  1). In this well-es-
tablished technique, the reduction in the minimum treatment concentration required to inhibit growth 
(MIC) is established for 2 compounds alone and in combination. The mutual reductions in MICs are 
used to calculate the fractional inhibitory concentration index (FICI), where a FICI ≤ 0.5 indicates syn-
ergism. Preliminary screening performed with Mycobacterium tuberculosis laboratory strain H37Rv 
indicated synergy (FICI ≤ 0.5) with 13 partner drugs, including trimethoprim, bacitracin, vancomy-
cin, tetracyclines, macrolides, and closely related lincosamides. Encouragingly, the finding of synergism 
between clarithromycin and 1599 is similar to previously reported synergism between clarithromycin 
and the parent drug spectinomycin28. Despite synergism with tetracyclines, 1599 did not synergize with 
the structurally-similar glycylcycline tigecycline (FICI = 0.6)29. Indifference (no antagonism) was seen 
between 1599 and aminoglycosides, beta-lactams, nitroimidazoles, and parent molecule spectinomycin. 
1599 neither synergized with nor sensitized cells to spectinomycin, suggesting that it’s avoidance of efflux 
by pump Rv1258c is not due to inhibition of this pump, as the later would be expected to sensitize TB 
to spectinomycin.
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Spectinamides synergize with tetracyclines, macrolides, and lincosamides to enhance 
potency against clinical isolates. Representative hits identified in initial screens were verified in 
checkerboard synergy assays against the laboratory M. tuberculosis Erdman strain and two clinical iso-
lates (Table 2). 1599 synergism with trimethoprim and the cyclic polypeptide bacitracin was restricted to 
laboratory strain H37Rv, as FICI scores determined for clinical isolates ranged from 0.8 to 2.0, indicating 
indifference. Synergism of 1599 and vancomycin was not tested in clinical isolates since this drug did 
not synergize with structurally related spectinamides (below), possibly indicating a non-specific inter-
action. The synergism of 1599 with clindamycin, clarithromycin, and doxycycline was maintained in 
clinical isolates. Synergism between clindamycin and 1599 was particularly notable, as clindamycin itself 
was inactive against all M. tuberculosis strains investigated (MIC ≥ 200 μ g/mL). Drugs synergistic with 
spectinamide 1599 were also tested for synergy with structurally related spectinamide compounds 1329 
and 1445 and their precursor, spectinomycin (Table 2). Synergy with clarithromycin, clindamycin, dox-
ycycline, and tetracycline was equivalent for all three spectinamides and spectinomycin, indicating the 
structural requirement for synergy was not introduced by the spectinamide modification to the parent 
molecule. Synergy with trimethoprim and vancomycin was restricted to compound 1599, however. This 




1599 MIC in 
combination




Acyl-depsipeptide ADEP4 > 20 20 0.6 ≤ 1.0 Indifference 1
Aminocycitol Spectinomycin 100–200 50–100 0.8 1.0 Indifference 2
Aminoglycoside Gentamycin 3.1 0.8 0.6 0.75 Indifference 1
Aminoglycoside Streptomycin 3.1 3.1–6.3 0.8–1.6 2.0–4.0 Indifference 2
Aminoglycoside Tobramycin 6.3 6.3 1.3 2.0 Indifference 1
Antifolate Methotrexate (DHFR) 200–> 200 100–200 1.3 0.75–≤ 2.0 Indifference 2
Antifolate Sulfamethoxazole (DHPS) 200 50 0.8 1.25 Indifference 1
Antifolate Trimethoprim (DHFR) > 200 12.5–25 0.2–0.3 ≤ 0.13–≤ 0.19 Synergism 3
Antiprotozoal Chloroquine > 200 > 200 2.5 ≤ 3.0 Indifference 1
Cephalosporin Cefotaxime > 200 > 200 1.3 ≤ 2.0 Indifference 1
Carbapenem Meropenem 6.3 6.3 1.3 ≤ 2.0 Indifference 1
Cyclic polypeptide Bacitracin > 200 25–50 0.6 ≤ 0.31–≤ 0.38 Synergism 2
Fluoroquinolone Gatifloxacin 0.2 0.1 0.6 1.0 Indifference 1
Glycopeptide Vancomycin 50 3.1 0.3–0.6 0.19–0.31 Synergism 2
Glycycline Tigecycline 6.3 0.8 0.6 0.6 Indifference 1
Lincosamide Clindamycin > 200–> 400 0.1–6.3 0.02–0.2 ≤0.02–≤0.16 Synergism 3
Lincosamide Lincomycin > 200 1.6–12.5 0.04–0.2 ≤0.07–≤0.16 Synergism 2
Lincosamide Pirlimycin > 200 25–50 0.3 ≤0.31–≤0.38 Synergism 2
Macrolide Azithromycin > 400–> 800 6.3–12.5 0.3–0.4 ≤0.13–≤0.28 Synergism 3
Macrolide Clarithromycin 12.5–48 0.1–5.6 0.04–0.05 0.07–0.35 Synergism 3
Macrolide Erythromycin > 200–800 12.5–50 0.2–0.4 0.16–≤0.28 Synergism 3
Nitroimidazole Metronidazole > 200 200 0.6 ≤1.0 Indifference 1
Nitroimidazole Nitrofurantoin 50 25 0.6 1.0 Indifference 1
Oxazolidinone Linezolid 3.1 3.1 0.1 1.5 Indifference 1
Tetracycline Doxycycline 6.3–50 0.4–0.8 0.1–0.3 0.08–0.31 Synergism 5
Tetracycline Minocycline 25 1.6 0.1 0.13 Synergism 1
Tetracycline Tetracycline 25–50 0.8–1.6 0.1–0.2 0.08–0.13 Synergism 2
Table 1.  In vitro synergism in Mycobacterium tuberculosis laboratory strain H37Rv. Whole cell, 
checkerboard assays were used to characterize interaction of 1599 with indicated antibiotics. Assays were 
performed with Mycobacterium tuberculosis strain H37Rv. Fractional Inhibitory Concentration Index (FICI) 
scores were interpreted as follows: synergy (≤ 0.5), indifference (> 0.5–4.0) or antagonism (> 4.0) and MICs 
are in μ g/mL. Results are presented as the range from the indicated number of biologically independent 
experimental replicates. A less than or equal to symbol (≤ ) preceding a FICI score indicates that an MIC 
was higher than the greatest concentration tested, which was used in FICI calculation.
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observation was not studied further since 1599 interaction with these drugs was not seen in clinical 
isolates and, therefore, is inappropriate for further advancement.
Synergism of 1599 and clarithromycin is achieved at relevant concentrations. An important 
consideration for the clinical potential of re-purposed antibiotics is if the concentration required to elicit 
the desired response, in this case synergy, is therapeutically achievable. To begin answering this question 
for the 1599 combinations identified, we examined the MIC of partner antibiotics in the presence and 
absence of 1599 (Table  3). The presence of sub-inhibitory 1599 (0.6 μ g/mL) reduced the MIC of the 
partner drugs examined by over 85%. For example, 1599 decreased the MIC of clarithromycin from 25 
to 0.1 μ g/mL. This is well below the maximum plasma concentration (Cmax) of clarithromycin achieved 
in humans (2.3 μ g/mL) receiving a single 200 mg oral dose of this antibiotic30. Sub-inhibitory concentra-
tions of 1599 also reduced the MIC of other antibiotics to equal or slightly above the Cmax parameters 
achieved in humans with a single oral dose of clindamycin (600 mg dose, 3.5 μ g/mL Cmax)31, Doxycycline 
(100 mg dose, 1.7 μ g/mL Cmax)32, and Tetracycline (300 mg dose, 2.5 μ g/mL Cmax)33. These data suggest 
that amongst the 1599 synergism partners identified, clarithromycin may have the greatest potential for 
synergism with spectinamides in vivo.
Co-administration of 1599 and clarithromycin provides a statistically significant improvement 
in clearance of pulmonary infection loads in an acute but not chronic mouse model of tuber-
culosis infection. Combinations were tested in vivo in a murine model of acute tuberculosis infec-
tion. Gamma-interferon knock-out (GKO) mice were infected by low dose aerosol and treatments were 
initiated 13 days post infection (p.i.) twice per day (BID) for 9 days (Fig. 1a). Monotherapy with 1599 
alone reduced bacterial loads in the lungs by 1.9 logs, similar to previous findings21. Clarithromycin alone 
reduced pulmonary loads by 1.7 logs despite having weak activity in vitro, which is in agreement with 
previous findings34 and may reflect this antibiotic’s high accumulation within lungs. Co-administration 
Antibiotic
FICI Score with 1599
FICI Score with other Spectinamides and 
Spectinamides (strain H37Rv)
Consensus 
InteractionH37Rv Erdman TN14149 TN043 1329 1445 Spectinomycin
Bacitracin ≤ 0.31–≤ 0.38 ≤ 1.06* ≤ 1.0* ≤ 0.75* nd nd nd Indifference
Clarithromycin 0.12–0.34 0.06–0.07 0.09–0.15 0.02* 0.003–0.02 0.03* 0.04–0.37 Synergism
Clindamycin ≤ 0.02–≤ 0.07 ≤0.03* ≤0.05* ≤0.05* ≤0.03–≤0.06 ≤0.03–≤0.06 ≤0.13–≤0.5 Synergism
Doxycycline 0.08–0.31 0.09 0.5* 0.25* 0.02* 0.02* 0.03–0.31 Synergism
Tetracycline nd nd nd nd 0.01* 0.02* 0.02 Synergism
Trimethoprim ≤0.13–0.19 ≤0.13* ≤2.0* ≤0.5* ≤0.75–≤2.0 ≤0.75–≤2.0 nd Indifference
Vancomycin nd nd nd nd 1.0–1.5 1.0 1.0 Indifference
Table 2.  Validation of Preliminary Hits. Whole cell, checkerboard assays were used to characterize 
interaction of spectinamides (1599, 1329, 1445) or parent spectinomycin with indicated antibiotics. Assays 
were performed with Mycobacterium tuberculosis laboratory strains (H37Rv, Erdman) or clinical isolates 
(TN14149, TN043), as indicated. Fractional Inhibitory Concentration Index (FICI) scores were interpreted 
as follows: synergy (≤ 0.5), indifference (> 0.5–4.0) or antagonism (> 4.0) and are representative of 2–3 




% MIC(−) 1599 (+) 1599
Clarithromycin 25–50 0.1 0.2–0.4%
Clindamycin > 200 6–25 <1.5–6.3%
Doxycycline 6.3–50 0.4–1.6 3.2–6.5%
Tetracycline 50 6.3 12.6%
Table 3.  Reduction in MIC produced by sub-inhibitory concentrations of compound 1599. MICs of 
macrolides and tetracyclines in the absence (− ) or presence (+ ) of 0.6 μ g/mL of spectinamide 1599. The 
% of original MIC values were calculated by dividing the MIC in the presence of 1599 by the MIC in the 
absence of 1599. Results presented are from two biologically independent experiments with Mycobacterium 
tuberculosis strain H37Rv.
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of 1599 with clarithromycin, however, yielded 2.8 logs of killing (Fig.  1a). This improvement in activ-
ity compared to monotherapy was statistically significant (p = 0.008 when compared to 1599 group) 
(Supplementary Table S1). Co-administration of 1599 with clindamycin or doxycyline did not yield a sta-
tistically significant difference in pulmonary loads in comparison with 1599 monotherapy (Supplementary 
Table S1)21.
The activity of 1599 (150 mg/kg), clarithromycin (250 mg/kg), and clindamycin (100 mg/kg) were then 
tested alone and in combination in a mouse model of chronic tuberculosis infection (Fig. 1b). Owing to 
the protracted nature of the chronic infection trial, it was impractical to dose animals more than once 
per day. Hence, BALB/c mice were infected by low dose aerosol and treatments were initiated 41 days 
p.i., once per day (QD), using a 5 of 7 (5/7) day dosing schedule for 30 days35,36. Compared to carrier 
treated controls, 1599 reduced bacterial loads by ~1.2 logs (p < 0.001 vs. carrier) in lungs, as we have 
reported previously (Fig. 1b, Supplementary Table S2). Monotherapy with clarithromycin or clindamycin, 
however, was completely ineffective at reducing bacterial load in the lungs. Co-administration of 1599 
with either clarithromycin or clindamycin failed to increase bacterial clearance as compared to 1599 
monotherapy and, in fact, slightly but significantly reduced the activity of 1599 in the lungs.
Inducible macrolide resistance may restrict efficacy in vivo with 5/7 day dosing. In light of the 
differing results for the combination of 1599 and clarithromycin in these two distinct infection models, 
mathematical modeling with the pharmacokinetic parameters of 1599 was performed retrospectively 
using plasma concentration-time data previously determined in mice after subcutaneous administration 
of 159921 (Fig. 2). Pharmacokinetic modeling was used to estimate plasma concentrations of 1599 when 
administered BID or QD to assess if the dosing schedule used in vivo may have negatively impacted the 
efficacy of this combination. The dosing schedule used in the acute infection model (BID dosing for 9 
consecutive days) was predicted to result in free plasma concentrations above the MIC of 1599 (defined 
here as >1 μ g/mL) for 7.9 h, representing 34% of the dosing interval. The remaining 66% of the time 
between doses (7.9 h), free plasma concentrations were predicted to be below MIC. In contrast the dos-
ing schedule used in the chronic infection trial (QD dosing 5/7 days) was predicted to result in periods 
below MIC of 68.3 h. Additionally, the total daily dose of 1599 and clarithromycin received was decreased 
by 50% compared to BID dosing when QD dosing was used. This also likely contributed to the lack of 
efficacy seen in chronic infection trial.
Exposure of mycobacteria to sub-inhibitory concentrations of macrolides (including clarithromycin) 
induces the bacterium’s erm methyltransferase activity that modifies the macrolide binding site to provide 
antibacterial resistance to this class of drugs. Since 5/7 dosing and lower dosing was predicted to cause 
periods of monotherapy in which clarithromycin may have induced its own resistance, we next deter-
mined if pre-exposure to clarithromycin prevented synergism with 1599. M. tuberculosis strains H37Rv 
and CDC1551 were pre-incubated for 24 hours with sub-inhibitory concentrations of clarithromycin or 
vehicle prior to performing checkerboard assays (Supplementary Table S3). The combination of 1599 and 
clarithromycin synergized against untreated H37Rv (FICIs ranged from 0.06 to 0.13), while synergism 
Figure 1. Efficacy of 1599 combinations in acute and chronic infection models. Log10 reduction in 
bacteria in lungs was determined by calculating the difference between bacillary loads in organs from the 
untreated group and treated groups. Mean log10 CFU reductions per lung ± the standard error of mean 
(SEM) are presented. (a) Murine model of acute tuberculosis infection where low-dose aerosol infected 
gamma interferon knock-out mice were treated twice a day for 9 consecutive days beginning 14 days post-
infection. (b) Murine model of chronic tuberculosis infection where low-dose aerosol infected BALB/c mice 
received treatments once daily for 5/7 days for 28 days beginning 41 days post-infection. Abbreviations: Clar, 
clarithromycin; Clind, clindamycin; Doxy, doxycycline.
www.nature.com/scientificreports/
6Scientific RepoRts | 5:13985 | DOi: 10.1038/srep13985
was greatly ablated in bacteria pre-treated with 0.1 μ g/mL clarithromycin (FICIs ranged from 0.65–1.0). 
Similar results were seen in separate experiments performed with strain CDC1551 (Supplementary Table 
S4). In the absence of clarithromycin pre-treatment, the lowest concentration of clarithromycin required 
to reduce the MIC of 1599 ranged from 0.1 to 0.8 μ g/mL, which is lower than clarithromycin’s maximum 
plasma concentration (3 μ g/mL) predicted in mice dosed orally at 200 mg/kg clarithromycin37. Once bac-
teria were exposed to monotreatment with clarithromycin (meant to simulate the 2 days off in a 5/7 dos-
ing schedule), the concentration of clarithromycin required to reduce the MIC of 1599 was > 50 μ g/mL 
in all experiments. This grossly exceeds the 3 μ g/mL peak plasma concentration of this antibiotic that is 
achievable in vivo. These data, combined with pharmacokinetic modeling, suggest that periods of clar-
ithromycin monotherapy resulting from mismatched exposure profiles restricted the synergism in vivo 
by induction of macrolide resistance.
1599 potentiates the potency of clarithromycin protein synthesis inhibition. To determine if 
the strong synergism seen between 1599 and clarithromycin in whole cell assays stemmed from inter-
actions at the ribosomal target, in vitro protein translation assays were performed using purified myco-
bacterial ribosomes. As comparators we included clindamycin and tetracyline, the two other ribosomal 
inhibitors shown to exhibit synergistic interaction with 1599 in whole cell assays. Titrations of 1599 
and partner drugs were prepared (6 concentrations per compound) and the percent inhibition resulting 
from each of the 36 unique drug concentration reactions measured (Supplementary Fig. S1). A mutual 
reduction on ribosomal IC50 was seen for the combination of 1599 and clarithromycin, where the IC50 
of clarithromycin was reduced from 1 to 0.2 μ g/mL in the presence of sub-IC50 1599. Although titration 
translation assays did indicate potentiation of protein translation inhibition, the magnitude of this inter-
action did not match the strong synergism seen in whole cell growth assays. However, among the three 
drug classes tested and shown to exhibit synergistic activity in whole cell assays, the interaction between 
1599 and clarithromycin was the most potent in the ribosomal target assay. Further studies may clarify 
if strong whole-cell synergism between 1599 and clarithromycin arises from an interaction independent 
of their known ribosomal binding sites as has been reported for streptogramin ribosome inhibitors38.
Discussion
In the present study, we identified several non-conventional anti-tuberculosis antibiotics that syner-
gized with the anti-tubercular spectinamide 1599 to inhibit growth of M. tuberculosis. Hits for whole 
cell (MIC-based) synergism were validated in clinical isolates, confirming in vitro synergism between 
spectinamides, tetracyclines, macrolides, and closely related lincosamides. The high attrition noted when 
Figure 2. Pharmacokinetic modeling. Free predicted 1599 plasma concentrations during efficacy trials. 
The MIC for 1599, 1 μ g/mL was used to defined the in vivo therapeutic concentration (blue line). Predicted 
plasma concentrations are shown in (a) for BID and (b) for QD dosing. (c) shows the maximum consecutive 
time of free 1599 concentrations below the MIC for each dosing regimen.
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validating H37Rv hits strongly emphasizes the need to confirm screening hits obtained using a laboratory 
strain by re-testing with clinical isolates. While in vitro synergism occurred at concentrations reportedly 
achievable in vivo, synergism was not strictly recapitulated when combinations were tested in mouse 
models of acute and chronic tuberculosis infection. Of the three drugs tested for synergism with 1599 
in vivo, only clarithromycin produced significant additive killing when combined with 1599 in the treat-
ment of an acute tuberculosis infection. This activity was restricted to the 9 day acute infection model, 
however, as the 1599-clarithromycin combination yielded weaker killing compared to monotherapy with 
1599 when tested in the model of chronic tuberculosis infection. This result was unanticipated, and 
underlines the need for further investigation to better understand the impact of inadequate clarithromy-
cin drug exposure in future combination dosing regimens.
Sufficient concentrations of antibiotic in the bloodstream and affected tissues following dose adminis-
tration are important for achieving synergism in vivo. Indeed, the importance of appropriately matched 
pharmacokinetic profiles – and the impact of mismatched exposure profiles - has been recently empha-
sized by the work of Drusano and others39. Mismatched exposure profiles can lead to periods of mono-
therapy, where bacteria are exposed to only the drug with the longer half-life. This can lead to periods 
of sub-inhibitory concentrations that may permit induction of transient resistance mechanisms and the 
selection of genetic mutants, as has been reported for the combination of rifampicin and moxifloxa-
cin in M. tuberculosis39. Indeed we demonstrate here that exposure of M. tuberculosis to subinhibitory 
concentrations of clarithromycin induces clarithromycin resistance and may lead to subsequent loss of 
synergism with 1599 in vivo. As the duration of treatment was extended from dosing BID for 9 con-
secutive days in the acute infection model to 28 days QD 5 days per week in the chronic infection 
model employed, it is therefore not surprising to see induction of phenotypic clarithromycin-resistance. 
The consequence of this was likely induction of transient macrolide resistance, associated loss of clar-
ithromycin efficacy, and subsequent loss of synergism with 1599. Modeling based upon known in vivo 
exposure profiles for the doses used also predicted that increasing dose frequency from once to twice 
daily and providing treatment 7 days per week should reduce periods in which macrolide resistance is 
induced in bacilli exposed only to clarithromycin thus enabling synergism in vivo. The lack of in vivo 
efficacy produced by these combinations when using a 5/7 day dosing regimen, however, may limit this 
combination to specific clinical situations where dosing and drug exposures are carefully monitored. 
Despite unclear efficacy, clarithromycin is included in salvage therapy for MDR tuberculosis when first 
and second line drugs fail40,41. Clarithromycin is well tolerated and has an acceptable toxicity profile, 
making it distinct from most second-line and salvage therapy agents42. While sub-inhibitory concentra-
tions of clarithromycin may induce phenotypic macrolide resistance, clarithromycin may offer additional 
benefits including its anti-inflammatory properties and positive influence on pharmacokinetics of orally 
co-administered antibiotics, including linezolid for which serum exposure in MDR TB patients increases 
with clarithromycin43, likely through increased oral bioavailability due to inhibition of P-gp mediated 
efflux. Therefore, future combination trials with clarithromycin should not be necessarily ruled out, but 
must involve carefully chosen and monitored dosing regimen to ensure optimal exposure. Alternatively, 
macrolide derivatives that do not induce macrolide resistance may improve prospects for combination 
treatment with anti-tuberculars, including spectinamides44.
The challenge of treating tuberculosis infections is complicated by numerous factors, including M. 
tuberculosis’s impermeable cell wall structure, and its ability to remain latent for decades walled off within 
granuloma. The complex tissue matrix surrounding granulomas represents a further obstacle that suc-
cessful anti-tuberculosis must permeate to reach resident bacteria45. This challenge is further exacerbated 
by findings indicating that a single granuloma is composed of several microenvironments and harbors a 
heterogeneous population of bacilli with distinct metabolic states and drug resistance profiles5. Careful 
design of drug combinations that do not necessarily synergize in the act of killing individual bacilli but 
rather reach and kill distinct bacterial subpopulations within the infected host, then, may lead to more 
complete sterilization and successful treatment. Therefore in vivo combination trials of 1599 with front-
line and developing tuberculosis drugs are of particular interest and ongoing in our laboratories.
Methods
Checkerboard synergy assays. Whole cell in vitro synergy assays were performed using M. tubercu-
losis strain H37Rv, which was cultured as described previously21. In a 96-well assay plate, two-fold serial 
dilutions of Drug A were prepared in 100 μ l of Middlebrook 7H9 media (highest and lowest concentra-
tions in rows A and G, respectively, with no drug in row H). Using a single dip with a 200ss pintool, 0.2 μ l 
of drug B (1599) was transferred to the assay plate columns 1 to 11 of the assay plate, with drug-free 
DMSO transferred to column 12. To each well of the assay plate 100 μ l of mid-log phase bacteria (diluted 
to OD600 of 0.01) was added, and plates incubated for 7 days prior to reading MICs by visual inspection. 
Fractional inhibitory concentration index (FICI) scores were calculated using the formula [MIC drug B 
in presence of Drug A]/[MIC of drug B) + [MIC of drug A in the presence of drug B]/[MIC of drug A]. 
FICI scores were interpreted as follows: synergy (≤ 0.5), indifference (> 0.5–4.0), or antagonism (> 4.0)28. 
For each drug combination, FICI ranges were reported from two biologically independent experiments.
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Ethics Statement. In vivo efficacy trials were performed at Colorado State University according to 
Protocol number 13-4263A, approved by the Colorado State University Institutional Animal Care and 
Use Committee (IACUC).
In vivo dosing selection for combination efficacy trails. Based upon promising in vitro syner-
gism, clarithromycin, clindamycin, and doxycycline were chosen for 1599 combination testing in an in 
vivo model of acute M. tuberculosis infection46. Dosing regimens were selected based on their tolerability 
and ability to generate therapeutically similar systemic exposures in vivo in mice to those reported in the 
literature for humans. For clindamycin, an oral dose of 100 mg/kg BID was chosen based on mouse PK 
and plasma protein binding data that indicted free peak plasma concentrations of approximately 4 μ g/mL 
for this dose47,48. For clarithromycin, an oral dose of 250 mg/kg BID was used, as this dosage was expected 
to result in free peak plasma concentrations of approximately 1 μ g/mL49,50. For doxycycline, oral admin-
istration of 150 mg/kg BID was used, with an expected peak of 0.3 μ g/mL for free concentrations51,52.
In vivo efficacy model of acute tuberculosis infection. Efficacy of antibiotics alone and in 
combinations was tested as essentially as described previously35,46,53. Briefly, 8 week female GKO mice 
(C57BL/6-IFNγ knockout from Jackson Laboratories) were infected with a low dose aerosol (LDA; 
~100 CFU’s per mouse) of M. tuberculosis Erdman, transformed with pFCA-LuxAB. Beginning 13 days 
post-infection mice were dosed with antibiotics twice daily (BID). Indicated groups of 5 mice per group 
received monotherapy with 1599 (subcutaneous injection, 150 mg/kg of body weight BID), clarithro-
mycin (oral delivery, 250 mg/kg BID), clindamycin (oral, 100 mg/kg BID), doxycycline (oral delivery, 
150 mg/kg BID), or 1599 dosing in combination with clarithromycin, clindamycin, or doxycycline at 
doses indicated for monotherapy. Mice were dosed for 9 consecutive days. 10 days post-initiation of 
treatment, lungs were harvested and bacterial loads determined by enumeration of CFU.
In vivo efficacy model of chronic tuberculosis infection. The combination of 1599 with clarithro-
mycin or with clindamycin was evaluated in a chronic infection, using female Balb/c mice (Charles River 
Labs, Wilmington, MA) infected with a LDA35,54–56. At 21 days post-infection, mice were treated once 
daily (QD) for 5 days a week (drug “holiday dosing”). Indicated groups of 6 mice per group received 
monotherapy with 1599 (subcutaneous injection, 150 mg/kg of body weight QD), clarithromycin (oral 
delivery, 250 mg/kg QD), clindamycin (oral, 100 mg/kg QD), of 1599 dosing in combination with clar-
ithromycin, or clindamycin, or doxycycline at doses indicated for monotherapy infection model. Lungs 
were harvested after 28 days of treatment and bacterial loads determined by enumeration of CFU.
Pharmacokinetic modeling. Plasma concentration-time profiles for 1599 were simulated using a 
2-compartment pharmacokinetic model based on pharmacokinetic data after subcutaneous administra-
tion in mice21. Simulations were performed for 5/7 and 7/7 day dosing with either QD and BID dosing 
using the software package Phoenix WinNonlin 6.3 (Icon Development Solutions, Hanover, MD).
Macrolide resistance induction. Checkerboard assays were performed in M. tuberculosis strains 
H37Rv and CDC1551 with and without pre-treatment with 0.1 μ g/mL of clarithromycin, a sub-inhibitory 
concentration that increases the resistance of mycobacteria to clarithromycin.
Ribosomal inhibition assays. Protein translation assays using mycobacterial ribosomes were per-
formed as described previously modified to measure the inhibition produced by combinations of two 
compounds57. For each drug combination, two-fold dilutions of compound 1599 were combined with 
two-fold dilutions of partner antibiotic to achieve 35 unique reaction concentration combinations where 
the concentration of each compound ranged from 1 to 1/16th the previously established ribosomal IC50.
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